UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
BTC and ETH have different launch timelines and development paths. This intro compares which is newer and what that means for investors and strategies.
20,975 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A harsh public claim about Val Kilmer’s behavior on a past project has reopened debates about how reputation affects ...
A Bloomberg-sparked rumor could change how AI compute is bought and sold. If Amazon starts selling its custom AI chip...
GM is navigating a tepid U.S. EV market, yet the company is pivoting toward energy storage and software. This article...
ExxonMobil stock surged January as energy markets moved higher, but the real story runs deeper than a single month. T...
NVIDIA’s AI surge is redefining the memory supply chain, and Micron investors face new headwinds. This deep dive expl...
A single month brought a sharp rally for Sirius XM as two big catalysts emerged: a new YouTube partnership expanding ...
A volatile start rattled tech stocks as the Nasdaq Composite faced a rough morning. This article breaks down why it h...
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
Artificial intelligence is reshaping finance, but the question isn’t simply disruption or protection. This article di...
In 2026, the VanEck Semiconductor ETF surprised many investors with standout performance. The real story isn’t just A...
Investors preparing for the Q4 2025 call on tarsus (tars) 2025 earnings will want a clear, actionable plan. This guid...